{"id":"cell-culture-rabies-vaccine","safety":{"commonSideEffects":[{"rate":"20–30","effect":"Local injection site reactions (pain, erythema, swelling)"},{"rate":"5–15","effect":"Headache"},{"rate":"5–10","effect":"Myalgia"},{"rate":"1–5","effect":"Fever"},{"rate":"1–5","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cell-culture rabies vaccines are produced by growing rabies virus in mammalian cell lines (such as Vero cells) rather than in animal neural tissue, then inactivating the virus. This approach generates a purified, safer immunogen that triggers both humoral (antibody) and cell-mediated immune responses to prevent rabies infection when administered post-exposure or pre-exposure.","oneSentence":"A cell-culture derived rabies vaccine that stimulates the immune system to produce antibodies and cellular immunity against rabies virus.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:44:49.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rabies post-exposure prophylaxis"},{"name":"Rabies pre-exposure prophylaxis"}]},"trialDetails":[{"nctId":"NCT02545517","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Evaluate Long-term Immunogenicity and Boostability of Purified Chick-Embryo Cell Rabies Vaccine in Adults Following Primary Series of Pre/Exposure Prophylaxis.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2015-10-05","conditions":"Virus Diseases, Rabies","enrollment":459},{"nctId":"NCT04232943","phase":"PHASE1","title":"Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults","status":"COMPLETED","sponsor":"PATH","startDate":"2020-01-22","conditions":"Polio","enrollment":87},{"nctId":"NCT03145766","phase":"PHASE2","title":"Immunogenicity and Safety of a Purified Vero Rabies Vaccine","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2017-04-17","conditions":"Rabies Virus","enrollment":320},{"nctId":"NCT02207816","phase":"PHASE3","title":"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2014-09-18","conditions":"Malaria","enrollment":3084},{"nctId":"NCT00866619","phase":"PHASE3","title":"Efficacy of GSK Biologicals' Candidate Malaria Vaccine 257049 Against Malaria Disease in Infants and Children in Africa","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-03-27","conditions":"Malaria","enrollment":15459},{"nctId":"NCT01148459","phase":"PHASE3","title":"Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-07-30","conditions":"Malaria","enrollment":200},{"nctId":"NCT01286493","phase":"NA","title":"Immune Response After Booster Vaccination in HIV - Infected Patients Who Received Rabies Primary Vaccination","status":"COMPLETED","sponsor":"Queen Saovabha Memorial Institute","startDate":"2011-02","conditions":"HIV, Rabies","enrollment":33}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VeroRab"],"phase":"phase_3","status":"active","brandName":"Cell-culture rabies vaccine","genericName":"Cell-culture rabies vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"A cell-culture derived rabies vaccine that stimulates the immune system to produce antibodies and cellular immunity against rabies virus. Used for Rabies post-exposure prophylaxis, Rabies pre-exposure prophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}